Compare Danaher Corporation (DHR) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs iShares Core MSCI EAFE ETF — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while iShares Core MSCI EAFE ETF trades at $96.52 (market cap $189.19B). The key difference: iShares Core MSCI EAFE ETF is the larger of the two by market cap, and Danaher Corporation pays a 0.74% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and iShares Core MSCI EAFE ETF for 40 Days on average.
| DHR | IEFA | |
|---|---|---|
Market Cap | $152.87B | $189.19B |
Volume | 5,228,698 | 8,441,787 |
Sector | Health | Broad Market / Factor |
52-Week High | $242.05 | $101.41 |
52-Week Low | $161.91 | $85.06 |
Typical Hold Time | 69 Days | 40 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
IEFA (iShares Core MSCI EAFE ETF) trades at $95.87, down 0.34% with bearish technical signals dominating. The ETF manages $196 billion in assets and focuses on developed markets outside North America. Recent comparisons highlight its higher dividend yield versus competitors like Schwab's SCHF and State Street's SPDW, though some alternatives have shown stronger recent performance.
The outlook remains cautious given bearish technical indicators and competitive pressure from lower-cost alternatives. Key risks include international market volatility and currency fluctuations, while the fund's scale and diversification provide stability for long-term international exposure seekers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
